145 related articles for article (PubMed ID: 21386838)
1. Resistance of uveal melanoma to the interstrand cross-linking agent mitomycin C is associated with reduced expression of CYP450R.
Gravells P; Hoh L; Canovas D; Rennie IG; Sisley K; Bryant HE
Br J Cancer; 2011 Mar; 104(7):1098-105. PubMed ID: 21386838
[TBL] [Abstract][Full Text] [Related]
2. Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts.
Cowen RL; Patterson AV; Telfer BA; Airley RE; Hobbs S; Phillips RM; Jaffar M; Stratford IJ; Williams KJ
Mol Cancer Ther; 2003 Sep; 2(9):901-9. PubMed ID: 14555709
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C.
Singh SV; Xu BH; Gupta V; Emerson EO; Zaren HA; Jani JP
Cancer Lett; 1995 Aug; 95(1-2):49-56. PubMed ID: 7656243
[TBL] [Abstract][Full Text] [Related]
4. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines.
Mikami K; Naito M; Tomida A; Yamada M; Sirakusa T; Tsuruo T
Cancer Res; 1996 Jun; 56(12):2823-6. PubMed ID: 8665520
[TBL] [Abstract][Full Text] [Related]
5. [Mechanism of resistance to mitomycin C in a human bladder cancer cell line].
Xu B; Sun Y; Singh SV
Zhonghua Zhong Liu Za Zhi; 1995 Sep; 17(5):343-6. PubMed ID: 8697971
[TBL] [Abstract][Full Text] [Related]
6. Tumor-specific synergistic therapy of mitomycin C: modulation of bioreductive activation.
Sakamoto N; Toge T; Nishiyama M
Hiroshima J Med Sci; 1997 Jun; 46(2):67-73. PubMed ID: 9232934
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy.
Basu S; Brown JE; Flannigan GM; Gill JH; Loadman PM; Martin SW; Naylor B; Scally AJ; Seargent JM; Shah T; Puri R; Phillips RM
Int J Cancer; 2004 May; 109(5):703-9. PubMed ID: 14999778
[TBL] [Abstract][Full Text] [Related]
8. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
9. Electrochemotherapy with bleomycin and cisplatin enhances cytotoxicity in primary and metastatic uveal melanoma cell lines in vitro.
Fiorentzis M; Kalirai H; Katopodis P; Seitz B; Viestenz A; Coupland SE
Neoplasma; 2018; 65(2):210-215. PubMed ID: 29534581
[TBL] [Abstract][Full Text] [Related]
10. Role of GRP58 in mitomycin C-induced DNA cross-linking.
Celli CM; Jaiswal AK
Cancer Res; 2003 Sep; 63(18):6016-25. PubMed ID: 14522930
[TBL] [Abstract][Full Text] [Related]
11. Molecular targeting of mitomycin C chemotherapy.
Nishiyama M; Suzuki K; Kumazaki T; Yamamoto W; Toge T; Okamura T; Kurisu K
Int J Cancer; 1997 Aug; 72(4):649-56. PubMed ID: 9259406
[TBL] [Abstract][Full Text] [Related]
12. Non-enzymatic and enzymatic activation of mitomycin C: identification of a unique cytosolic activity.
Joseph P; Xu Y; Jaiswal AK
Int J Cancer; 1996 Jan; 65(2):263-71. PubMed ID: 8567127
[TBL] [Abstract][Full Text] [Related]
13. Regulatory network of mitomycin C action in human colon cancer cells.
Suzuki K; Yamamoto W; Park JS; Hanaoka H; Okamoto R; Kirihara Y; Yorishima T; Okamura T; Kumazaki T; Nishiyama M
Jpn J Cancer Res; 1999 May; 90(5):571-7. PubMed ID: 10391098
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a human bladder cancer cell line selected for resistance to mitomycin C.
Xu BH; Gupta V; Singh SV
Int J Cancer; 1994 Sep; 58(5):686-92. PubMed ID: 8077054
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor.
Wang Y; Liu M; Jin Y; Jiang S; Pan J
Cancer Lett; 2017 Aug; 400():47-60. PubMed ID: 28455241
[TBL] [Abstract][Full Text] [Related]
16. Formation of DNA interstrand cross-links as a marker of Mitomycin C bioreductive activation and chemosensitivity.
Volpato M; Seargent J; Loadman PM; Phillips RM
Eur J Cancer; 2005 Jun; 41(9):1331-8. PubMed ID: 15869876
[TBL] [Abstract][Full Text] [Related]
17. Lack of correlation between repair of DNA interstrand cross-links and hypersensitivity of hamster cells towards mitomycin C and cisplatin.
Larminat F; Cambois G; Zdzienicka MZ; Defais M
FEBS Lett; 1998 Oct; 437(1-2):97-100. PubMed ID: 9804179
[TBL] [Abstract][Full Text] [Related]
18. Modification of the alkaline Comet assay to allow simultaneous evaluation of mitomycin C-induced DNA cross-link damage and repair of specific DNA sequences in RT4 cells.
McKenna DJ; Gallus M; McKeown SR; Downes CS; McKelvey-Martin VJ
DNA Repair (Amst); 2003 Aug; 2(8):879-90. PubMed ID: 12893084
[TBL] [Abstract][Full Text] [Related]
19. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors.
Gan Y; Mo Y; Kalns JE; Lu J; Danenberg K; Danenberg P; Wientjes MG; Au JL
Clin Cancer Res; 2001 May; 7(5):1313-9. PubMed ID: 11350900
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
